ReviewFrontiers in pharmacology2026
Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) propelled EGFR-mutated patients of non-small cell lung cancer (NSCLC) into the era of precision medicine. Third-generation targeted therapies, such as osimertinib, can specifically target the T790M mutation and effectively overcome resistance to previous treatments, significantly prolonging progression-free survival in patients. Despite its remarkable clinical efficacy and manageable safety profile, it is still not immune to the development of resistance. Therefore, overcoming resistance and providing new treatment strategies for advanced NSCLC patients harboring EGFR mutations after osimertinib resistance are priorities that need to be considered. New-generation EGFR-TKIs or combination therapeutic strategies hold promise to address resistance. In addition, with the development of genomics and molecular diagnostic technologies, several drugs with novel mechanisms of action, such as antibody-drug conjugates and bispecific antibodies, have shown promising clinical response rates and favorable safety profiles in several clinical and experimental studies. This review aims to more systematically indicate the mechanisms of EGFR-TKI resistance and summarize the new strategies available and novel drugs under investigation for NSCLC patients harboring EGFR mutations after TKI resistance to extend their survival and improve quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.